<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[2, 8] triglyceride/high-density lipoprotein cholesterol ratio<br>[19, 21] coronary atherosclerosis<br>[128, 131] Coronary atheroma progression<br>[141, 154] changes in biochemical parameters, percent atheroma volume, and total atheroma volume<br>[167, 191] high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein.<br>[196, 203] changes in percent atheroma volume and triglycerides<br>[213, 217] triglyceride/HDL-C ratio<br>[228, 230] glycated hemoglobin<br>[243, 250] changes in low-density lipoprotein cholesterol<br>[260, 262] apolipoprotein B<br>[273, 274] apolipoprotein<br>[304, 307] HDL-C<br>[322, 323] triglycerides<br>[335, 339] triglyceride/HDL-C ratio<br>[353, 355] glycated hemoglobin<br>[385, 386] atheroma<br>[394, 395] atheroma<br>[410, 413] triglyceride/HDL-C<br>[417, 419] atheroma progression<br></td>
<td width=33%>
[2, 8] triglyceride/high-density lipoprotein cholesterol ratio<br>[17, 21] progression of coronary atherosclerosis<br>[64, 67] atheroma progression.<br>[75, 79] coronary atheroma progression.<br>[128, 131] Coronary atheroma progression<br>[141, 154] changes in biochemical parameters, percent atheroma volume, and total atheroma volume<br>[167, 191] high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein.<br>[196, 203] changes in percent atheroma volume and triglycerides<br>[213, 217] triglyceride/HDL-C ratio<br>[228, 230] glycated hemoglobin<br>[243, 250] changes in low-density lipoprotein cholesterol<br>[260, 262] apolipoprotein B<br>[273, 274] apolipoprotein<br>[290, 293] atheroma regression,<br>[304, 307] HDL-C<br>[322, 323] triglycerides<br>[335, 339] triglyceride/HDL-C ratio<br>[353, 355] glycated hemoglobin<br>[376, 379] triglyceride/HDL-C<br>[384, 387] percent atheroma volume<br>[393, 396] total atheroma volume<br>[410, 414] triglyceride/HDL-C ratio<br>[417, 419] atheroma progression<br>[431, 433] atherogenic dyslipidemia<br></td>
<td width=33%>
[2, 8] triglyceride/high-density lipoprotein cholesterol ratio<br>[17, 21] progression of coronary atherosclerosis<br>[64, 67] atheroma progression.<br>[75, 79] coronary atheroma progression.<br>[128, 131] Coronary atheroma progression<br>[134, 138] serial intravascular ultrasound.<br>[139, 154] relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume<br>[164, 191] greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein.<br>[196, 203] changes in percent atheroma volume and triglycerides<br>[213, 217] triglyceride/HDL-C ratio<br>[228, 230] glycated hemoglobin<br>[241, 250] , and changes in low-density lipoprotein cholesterol<br>[260, 262] apolipoprotein B<br>[273, 274] apolipoprotein<br>[275, 277] -I<br>[289, 293] Substantial atheroma regression,<br>[295, 297] progression,<br>[301, 307] relative increases in HDL-C<br>[322, 323] triglycerides<br>[335, 339] triglyceride/HDL-C ratio<br>[353, 355] glycated hemoglobin<br>[374, 379] effects on triglyceride/HDL-C<br>[382, 388] changes in percent atheroma volume (<br>[393, 396] total atheroma volume<br>[410, 414] triglyceride/HDL-C ratio<br>[416, 419] delayed atheroma progression<br>[431, 433] atherogenic dyslipidemia<br></td>
</tr>
